Skip to main content

Table 1 Characteristics of individuals included in the study

From: Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study

  N (%) Total person-years of follow-up
Total number of cases included in analysis 28,260 239,125.95
Female 14,678 (51.9)  
Age at IBD diagnosis
 Diagnosed ≤ 65 years 17,662 (62.5)  
 Diagnosed ≥ 65 years 5554 (19.7)  
 Unknowna 5044 (17.9)  
Rural residenceb 4344 (15.4)  
Mean neighbourhood income quintile
 Q1 4678 (16.7)  
 Q2 5420 (19.4)  
 Q3 5642 (20.2)  
 Q4 5662 (20.3)  
 Q5 6547 (23.4)  
Drug group
 Immunomodulator Monotherapy 4789 (16.9) 12,141.96
 Biologic Monotherapy 1381 (4.9) 3010.39
 Combination therapy 844 (3.0) 1764.27
 Mesalamine 17,625 (62.4) 81,128.99
 No therapy 28,260 (100.0) 95,492.74
 Systemic steroids 14,647 (51.8) 12,220.14
Type of IBD
 Crohn’s disease 10,870 (38.5) n/a
 Ulcerative colitis 15,992 (56.6) n/a
 IBD-type unclassified 1398 (4.9) n/a
  1. IBD inflammatory bowel disease
  2. aFirst diagnostic code for IBD occurred ≥ 65 years of age but did not have an 8-year washout period prior to first IBD code
  3. bAt first diagnostic code for IBD